Tag: HP-MAP
Vaxxas’ needle-free seasonal influenza vaccine enters clinical trial
Vaxxas has commenced the Phase I clinical trial of the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate via its proprietary high-density microarray patch (HD-MAP) technology.
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
